GlassScriptPhysician profile
Peter M Varunok
NPI 1598769283
$17,236.73
in general payments reported to CMS, 2019-2025
27 companies · $767 in 2025
The $767 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $907 · 2021: $230 · 2022: $360 · 2023: $765 · 2024: $655 · 2025: $767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,156 · Education: $30.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,156.21 |
| Education | $30.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $13,573.88 | 2019-2025 | Livdelzi |
| Abbvie INC. | $1,499.56 | 2019-2025 | Mavyret, Rinvoq, Skyrizi |
| Romark Laboratories, Lc | $319.52 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $315.26 | 2019-2023 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $242.22 | 2019-2023 | Xifaxan |
| Qol Medical, LLC | $181.54 | 2019-2025 | Sucraid |
| Ironwood Pharmaceuticals, INC | $166.34 | 2023-2024 | Linzess |
| Pfizer INC. | $146.77 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $143.92 | 2019-2024 | Entyvio |
| Janssen Biotech, INC. | $95.87 | 2019-2023 | Stelara |
| Boston Scientific Corporation | $73.05 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $72.63 | 2025 | Iqirvo |
| Ferring Pharmaceuticals INC. | $54.75 | 2024-2025 | Rebyota |
| Braintree Laboratories, INC. | $49.35 | 2019-2023 | Sutab |
| Genzyme Corporation | $43.82 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $36.29 | 2019-2024 | Dificid |
| Madrigal Pharmaceuticals | $33.75 | 2024 | Resmetirom |
| Lilly USA, LLC | $28.79 | 2024 | Omvoh |
| Cook Medical LLC | $28.32 | 2019 | |
| W. L. Gore & Associates, INC. | $25.23 | 2025 | Gore Cardioform Septal Occluder |
| Novo Nordisk INC | $22.08 | 2025 | Wegovy |
| Ardelyx, INC. | $21.03 | 2025 | Ibsrela |
| Celltrion USA INC. | $14.36 | 2024 | Vegzelma |
| Fresenius Kabi USA, LLC | $12.97 | 2023 | |
| Curium US LLC | $12.92 | 2022 | |
| Currax Pharmaceuticals LLC | $11.26 | 2021 | |
| Ucb, INC. | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Varunok listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.